“We believe that we can provide life-changing treatments to the many thousands of patients suffering from these serious chronic lung infections. We are intensely focused on delivering effective treatments to these patients as quickly as possible.”
– Will Lewis, President and CEO
We are a publicly traded (NASDAQ: INSM) biopharmaceutical company dedicated to improving the lives of patients battling serious lung diseases. We are focused on the development and commercialization of novel, targeted inhaled therapies for patients with high unmet need battling orphan lung diseases.
Our lead product candidate, ARIKACE (liposomal amikacin for inhalation), is designed to treat rare lung infections in patients who have limited alternatives for treatment. ARIKACE is a differentiated, inhaled antibiotic engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the efficacy, safety and convenience of treatment for patients.
Currently, we are continuing late-stage clinical trials for two initial primary target orphan indications for this product: lung infections caused by Pseudomonas in CF patients and lung infections caused by NTM. We expect to report clinical results from both clinical trials in 2013. Our sole development focus is to obtain regulatory approval for ARIKACE and to prepare for its commercialization in the US, Canada and Europe.
*Administered once daily using an optimized eFlow® Electronic Nebulizer (PARI Pharma GmbH).